Search

Corcept Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

109.34 -2.43

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

108.84

Max

112.91

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-130M

-32M

Pardavimai

-37M

165M

P/E

Sektoriaus vid.

260.343

64.641

Pelnas, tenkantis vienai akcijai

-0.3

Pelno marža

-19.26

Darbuotojai

730

EBITDA

-55M

-44M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+8.69% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.8B

9.8B

Ankstesnė atidarymo kaina

111.77

Ankstesnė uždarymo kaina

109.34

Corcept Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-04 19:16; UTC

Corcept Therapeutics Inc shares are lower today, continuing a decline seen over the past three trading days. No specific news was identified for the drop.

2026-08-03 20:02; UTC

Corcept Therapeutics Inc shares are lower today amid a decline in the Pharmaceuticals sub-sector, with unusually high trading volume noted.

2026-07-31 22:26; UTC

Corcept Therapeutics shares are higher in after-market hours, peaking shortly after Friday's close despite no specific news to explain the movement.

2026-07-30 23:11; UTC

Corcept Therapeutics shares traded lower in after-market hours, reflecting broader market uncertainty following the Federal Reserve's interest rate decision.

2026-07-29 23:41; UTC

Social Media
News

Corcept Therapeutics shares are trading higher in after-market hours following strong second-quarter results, with revenue of $256.1 million and raised full-year guidance.

2026-07-28 19:46; UTC

News

Corcept Therapeutics shares are higher ahead of Q2 earnings tomorrow, with analysts expecting revenue growth to slow to 8.4% year-on-year.

2026-07-27 23:46; UTC

Shares of Corcept Therapeutics Inc declined in after-hours trading, dipping to a low shortly after the market reopened. No specific news was identified.

2026-07-24 21:01; UTC

Corcept Therapeutics shares are lower in after-market trading, reflecting broader negative sentiment following earnings reports from major companies like Tesla and Alphabet.

2026-07-22 19:51; UTC

Corcept Therapeutics Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is affected by rising crude oil prices and geopolitical tensions.

2026-07-21 17:06; UTC

Corcept Therapeutics Inc is trading higher today, reflecting broader market trends as regional indices like the Nikkei 225 also show gains.

2026-07-20 18:13; UTC

Social Media

Corcept Therapeutics shares are higher today, boosted by FDA approval of Lifyorli and increased trading volume amid heightened investor interest.

Akcijų palyginimas

Kainos pokytis

Corcept Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

8.69% į viršų

12 mėnesių prognozė

Vidutinis 122.6 USD  8.69%

Aukščiausias 165 USD

Žemiausias 50 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corcept Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

4

Pirkti

0

Laikyti

1

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.
help-icon Live chat